ARQT News and Press, Arcutis Biotherapeutics Inc. From 11/05/20

Pivotal Phase 3 data in plaque psoriasis anticipated in first quarter of 2021 Pivotal Phase 3 trials in atopic dermatitis anticipated to begin in late 2020 or early 2021 Recent positive Phase 2 data in seborrheic dermatitis supports pipeline advancement in indication that impacts ...

WESTLAKE VILLAGE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that Terrie Curran has ...

Arcutis Biotherapeutics ([[ARQT]] +1.8%) announces new positive data from two Phase 2 clinical trials evaluating ARQ-151 (topical roflumilast cream) in patients with chronic plaque psoriasis and atopic dermatitis ((AD)). The results are being virtually presented at the European Academy o...

In Phase 2b study of patients with plaque psoriasis, roflumilast cream demonstrated rapid and clinically significant reduction in the severity and burden of itch and itch-related sleep loss as well as rapid improvement in patient-reported symptom burden Phase 2 proof-of-concept study ...

Arcutis has an upcoming phase 3 data readout catalyst in 1Q 2021. Past data has been good, with a clear competitive difference. However, low cash and competition makes this a cautious investment, albeit with potential for high rewards. For further details see: Arcutis Bi...

Data highlight potential of roflumilast cream as a “Best in Class” topical PDE4 inhibitor for the treatment of atopic dermatitis and plaque psoriasis Two oral presentations and one poster at the European Academy of Dermatology and Venereology Virtual Congress Data to...

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Hand eczema is the most common skin disease affecting the hands, impacting more than 8 million Americans Topline data now anticipated by mid-20...

WESTLAKE VILLAGE, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatol...

Gainers: American Renal Associates (ARA) +68%.IDT (IDT) +37%.Nano-X Imaging (NNOX) +36%.Westwater Resources (WWR) +24%.voxeljet (VJET) +21%.Houghton Mifflin Harcourt (HMHC) +21%.ProPhase Labs (PRPH) +19%.Lithium Americas (LAC) +19%.Telenav (TNAV) +18%.Assured Guaranty (AGO) +17...

Shares of Arcutis Biotherapeutics (NASDAQ: ARQT) are down by 14.3% as of 12:12 p.m. EDT on Friday, after the company announced the pricing of a public offering of common stock. Investors typically react to stock offerings by selling off shares of the company in question, and it isn'...